Bosutinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
87.22
Gini
0.555
CATDS
0.008
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Bosutinib. Strongest target: ACK1 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ACK1 | 100.0% | 0.0% |
| 2 | BLK | 100.0% | 0.0% |
| 3 | C_SRC | 100.0% | 0.0% |
| 4 | FRK_PTK5 | 100.0% | 0.0% |
| 5 | KHS_MAP4K5 | 100.0% | 0.0% |
| 6 | MINK_MINK1 | 100.0% | 0.0% |
| 7 | HGK_MAP4K4 | 100.0% | 0.0% |
| 8 | ERBB4_HER4 | 99.9% | 0.1% |
| 9 | EPHB2 | 99.8% | 0.2% |
| 10 | ABL1 | 99.7% | 0.3% |
| 11 | FYN | 99.7% | 0.3% |
| 12 | EPHA2 | 99.7% | 0.3% |
| 13 | LCK | 99.7% | 0.3% |
| 14 | TNIK | 99.6% | 0.4% |
| 15 | SIK2 | 99.6% | 0.4% |
| 16 | EPHA4 | 99.6% | 0.4% |
| 17 | HCK | 99.6% | 0.4% |
| 18 | EPHB1 | 99.5% | 0.5% |
| 19 | CSK | 99.5% | 0.5% |
| 20 | BTK | 99.3% | 0.7% |
Selectivity landscape
Where Bosutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Bosutinib.
Annotations
Sign in to read and post annotations.
Loading…